Welch & Forbes LLC increased its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 75,476 shares of the medical instruments supplier’s stock after purchasing an additional 480 shares during the quarter. Welch & Forbes LLC’s holdings in Becton Dickinson and were worth $20,527,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of the stock. Compass Ion Advisors LLC bought a new stake in shares of Becton Dickinson and in the fourth quarter worth $226,000. We Are One Seven LLC lifted its holdings in Becton Dickinson and by 29.5% in the fourth quarter. We Are One Seven LLC now owns 1,068 shares of the medical instruments supplier’s stock valued at $290,000 after buying an additional 243 shares during the period. Wedbush Securities Inc. lifted its holdings in Becton Dickinson and by 2.3% in the fourth quarter. Wedbush Securities Inc. now owns 3,308 shares of the medical instruments supplier’s stock valued at $900,000 after buying an additional 75 shares during the period. Hemenway Trust Co LLC lifted its holdings in Becton Dickinson and by 16.1% in the fourth quarter. Hemenway Trust Co LLC now owns 49,123 shares of the medical instruments supplier’s stock valued at $13,360,000 after buying an additional 6,810 shares during the period. Finally, Broderick Brian C lifted its holdings in Becton Dickinson and by 39.4% in the fourth quarter. Broderick Brian C now owns 8,611 shares of the medical instruments supplier’s stock valued at $2,341,000 after buying an additional 2,435 shares during the period. 84.46% of the stock is currently owned by institutional investors.
Shares of NYSE BDX traded up $0.49 during trading on Friday, hitting $277.36. 393,205 shares of the company traded hands, compared to its average volume of 1,284,627. The business’s fifty day moving average is $268.24 and its 200 day moving average is $256.22. Becton Dickinson and Co has a fifty-two week low of $221.47 and a fifty-two week high of $279.62. The firm has a market capitalization of $74.64 billion, a price-to-earnings ratio of 23.75, a P/E/G ratio of 1.97 and a beta of 1.07. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, beating the consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The firm had revenue of $4.58 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter in the prior year, the business earned $2.93 earnings per share. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. On average, analysts predict that Becton Dickinson and Co will post 12.57 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Tuesday, December 10th were issued a dividend of $0.79 per share. The ex-dividend date was Monday, December 9th. This represents a $3.16 annualized dividend and a dividend yield of 1.14%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. Becton Dickinson and’s dividend payout ratio is currently 27.05%.
BDX has been the topic of several recent analyst reports. Barclays lowered shares of Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 target price on the stock. in a report on Wednesday, January 8th. KeyCorp dropped their target price on shares of Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. JPMorgan Chase & Co. boosted their target price on shares of Becton Dickinson and from $285.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Morgan Stanley boosted their target price on shares of Becton Dickinson and from $261.00 to $287.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. Finally, Stifel Nicolaus boosted their target price on shares of Becton Dickinson and from $275.00 to $295.00 and gave the company a “buy” rating in a report on Monday, December 16th. Six analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $277.70.
In other news, CEO Vincent A. Forlenza sold 11,626 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $265.57, for a total transaction of $3,087,516.82. Following the transaction, the chief executive officer now owns 225,393 shares in the company, valued at $59,857,619.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick Kaltenbach sold 339 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $263.23, for a total transaction of $89,234.97. Following the transaction, the executive vice president now owns 19,546 shares in the company, valued at approximately $5,145,093.58. The disclosure for this sale can be found here. Insiders have sold 91,231 shares of company stock worth $24,787,690 in the last quarter. Company insiders own 0.12% of the company’s stock.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Article: Cost of Goods Sold (COGS)
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.